🔴 Cue Biopharma extends decline after $50M private placement announced last week

Cue Biopharma is trading at $25.50 (8.2% down) in pre-market, extending a sharp pullback this week.

• The ongoing decline follows the company's announcement of a $50 million private placement of common stock and pre-funded warrants on July 10, 2026.
• Investors are reacting to dilution concerns stemming from this offering, which is seen as the primary driver for the stock's pressure this week.
• The private placement was expected to close on or about July 13, 2026.